e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Comfort, safety and effectiveness of bronchoscopy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The utility of bronchoscopically acquired tissue for successful lung cancer molecular profiling (LC-MP)
Y. Zhang, M. Zeng, P. Illei, Q. Li, Z. Maleki, C. Adams, A. Novak, S. Otell, R. Yung (Baltimore, United States Of America; Shanghai, China)
Source:
Annual Congress 2013 –Comfort, safety and effectiveness of bronchoscopy
Session:
Comfort, safety and effectiveness of bronchoscopy
Session type:
Thematic Poster Session
Number:
3776
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Zhang, M. Zeng, P. Illei, Q. Li, Z. Maleki, C. Adams, A. Novak, S. Otell, R. Yung (Baltimore, United States Of America; Shanghai, China). The utility of bronchoscopically acquired tissue for successful lung cancer molecular profiling (LC-MP). Eur Respir J 2013; 42: Suppl. 57, 3776
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
mRNA biomarker screening in pulmonary tumors showing neuroendocrine differentiation
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Optimization of cfDNA routine use for NSCLC genomic alteration analysis
Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease
Year: 2016
Development of an invasive 3D lung tumor model for oncological research
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Telomere-associated gene network in lung adenocarcinoma
Source: International Congress 2015 – Respiratory translational research: novel mechanisms, diagnostic markers and Space Odyssey
Year: 2015
Prevalence of molecular changes in resected pulmonary adenocarcinomas
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Molecular profiling of lung squamous carcinogenesis
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
Dividing EBUS-TBNA samples for simultaneous histopathological and molecular analyses in lung cancer patients
Source: International Congress 2015 – Endoscopic ultrasound: an essential tool for interventional pulmonology
Year: 2015
Exploiting metabolomic approaches to aid in the diagnosis of lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Significance of expression of TGF-β in pulmonary metastasis in non-small cell lung cancer tissues
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Plasma cell-free DNA concentration and integrity analysis in patients with chest radiological findings: NSCLC versus non-malignant pathologies
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Comparative analysis of lung cancer driver mutations from FFPE samples and liquid biopsies by IonTorrent next generation sequencing
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC
Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer
Year: 2013
High-throughput detection of alternative splicing in patients with non-small cell lung cancer treated by bevacizumab/erlotinib
Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer
Year: 2014
Metabolic modification as a potential therapeutics approach in lung cancer
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Determining genomic rearrangements in clinical lung specimens for assessment of metastatic disease, actionable targets and disease monitoring
Source: International Congress 2016 – New genomic targets in pulmonary disease
Year: 2016
Expression and clinical implications of the estrogen receptor β in lung adenocarcinoma
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept